BCAB 250117 7.50P (BCAB250117P7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

BCAB250117P7500

Watchlist

5.77
0.000.00%

15min DelayTrading Sep 18 10:56 ET

0.00High0.00Low

Intraday

5D
Daily

News

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know
Yahoo FinanceJan 2 12:00 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaDec 20, 2024 16:06 ET
BioAtla Prices Registered Direct Offering of 9.7 Million Shares for Expected Gross Proceeds of $9.2 Million
MT NewswiresDec 20, 2024 10:23 ET
BioAtla Highlights Advancements in CAB Cancer Therapy
TipRanksDec 20, 2024 09:17 ET
Express News | BioAtla Announces $9.2M Registered Direct Offering Of 9,679,158 Shares At $1.19/Share
BenzingaDec 20, 2024 09:01 ET
Express News | Bioatla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
ReutersDec 20, 2024 09:00 ET

Comments

030611232530

Dec 19, 2024 01:22

$BioAtla (BCAB.US)$ hopeless going into delisting?

Jaguar8

Dec 16, 2024 07:05

NEWS

$BioAtla (BCAB.US)$
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Monday, 16th December at 8:00 am
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treat...

030611232530

Nov 12, 2024 09:17

$BioAtla (BCAB.US)$ ya some gemoks like to short theirs off

NEWS

$BioAtla (BCAB.US)$
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown ...